v3.25.2
Note 16 - Geographic and Segment Information - Profit and Loss Information by Reportable Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Total revenue $ 27 $ 91 $ 108 $ 164
Cost of revenue 0 18 20 34
Research and development 3,514 4,150 4,995 10,019
Depreciation 366 414 770 834
Total stock-based compensation expense 1,367 1,951 3,314 3,964
Segment loss from operations (5,864) (7,391) (9,940) (16,623)
General and Administrative Expense [Member]        
Depreciation 29 67 95 133
Total stock-based compensation expense 767 1,048 1,768 2,184
Operating Segments [Member]        
Total revenue 27 91 108 164
Cost of revenue 0 18 20 34
Facilities 386 401 805 782
Depreciation 337 347 675 701
Manufacturing 187 422 270 661
Research 2 141 7 316
Equipment 14 35 28 64
Maintenance 32 17 64 37
Information technology 54 29 119 66
Personnel 2,100 2,545 4,260 5,209
Total stock-based compensation expense 600 903 1,546 1,780
Grant revenue as a reduction of research and development expense (2,058) (1,723) (6,225) (2,002)
Other segment items - Research and development(1) [1] 79 30 104 59
Segment loss from operations (5,864) (7,391) (9,940) (16,623)
Operating Segments [Member] | General and Administrative Expense [Member]        
Facilities 31 31 61 63
Depreciation 29 67 95 133
Information technology 47 87 96 166
Total stock-based compensation expense 767 1,048 1,768 2,184
Grant revenue as a reduction of research and development expense (65) (106) (228) (106)
Insurance 181 187 362 373
Legal 175 284 323 359
Finance and accounting 220 124 530 373
Public and investor relations 119 199 230 433
Personnel 788 1,044 1,620 2,140
Other segment items - General and administrative(2) [2] 85 349 176 616
Operating Segments [Member] | CNM-Au8, Amyotrophic Lateral Sclerosis [Member]        
Research and development 1,468 610 2,811 1,380
Operating Segments [Member] | CNM-Au8, Multiple Sclerosis [Member]        
Research and development 164 69 189 161
Operating Segments [Member] | CNM-Au8, Parkinson's Disease [Member]        
Research and development 0 2 0 2
Operating Segments [Member] | CNM-Au8, Regulatory Activities [Member]        
Research and development 130 122 260 462
Operating Segments [Member] | CNM-Au8, General, Pre-clinical, and Non-clinical [Member]        
Research and development 19 200 82 328
Operating Segments [Member] | CNM-ZnAg [Member]        
Research and development 0 0 0 13
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]        
Segment loss from operations $ 0 $ 0 $ 0 $ 0
[1] Includes expenses for travel, meals, dues, subscriptions, continuing education, and other miscellaneous expenses.
[2] Includes expenses for travel, meals, dues, subscriptions, continuing education, lobbying, banking fees, postage, and other office and miscellaneous expenses.